NSE: SUNPHARMA | BSE: 524715

Mid-range Performer

Download real time

1662.50 -6.90 (-0.41%)

1.8M NSE+BSE Volume

NSE 10 Jul, 2025 3:31 PM (IST)

398,889.4

Market Cap

Market Leader

0.6

Beta 1Year

Very Low volatility

Sun Pharmaceutical Industries Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for SUNPHARMA, BSE:524715 Sun Pharmaceutical Industries Ltd.

Search Inside the pdf :

Sun Pharmaceutical Industries Ltd.

23 May 2025

1662.50

-0.41%

Sun Pharma (BUY): Specialty launches to contribute 20% of global specialty sales

Buy: Sun Pharmaceutical Industr...

Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT were lower than our estimates by 3.5%/9.6%/29.4%. ETR for 4QFY25 stood at 32.9% including 1x tax expense of Rs 3.7bn

Promoters pledged 0.19% of shares in last quarter. Total pledge stands at 0.88% of promoter holdings

Sun Pharmaceutical Industries Ltd.

23 May 2025

1662.50

-0.41%

India/EM outperformers; US/ROW underperformers

Buy: Sun Pharmaceutical Industr...

Target

Motilal Oswal

Sun Pharmaceutical Industries (SUNP) delivered 4%/9%/4% miss on revenue/EBITDA/PAT for 4QFY25. Lower-than-expected sales in global specialty and ROW led to a miss on 4QFY25 performance.

Promoters pledged 0.19% of shares in last quarter. Total pledge stands at 0.88% of promoter holdings

Sun Pharmaceutical Industries Ltd.

23 May 2025

1662.50

-0.41%

Sun Pharmaceutical Industries (SUNP IN) Q4FY25 Result Update ...

Buy: Sun Pharmaceutical Industr...

Target

Prabhudas Lilladhar

Sun Pharma (SUNP) Q4FY25 EBIDTA (+11% YoY) was largely in line however moderate growth (9% YoY) in specialty sales after several quarters of strong double-digit growth was below our estimate. Over last few years SUNP dependency on US generics has reduced and company's growth is more functional on specialty, RoW and domestic pharma that has strong growth visibility. Though FY26 expenses (an additional $100mn spend) is likely to remain elevated given company are in investment phase to ramp up specialty...

Promoters pledged 0.19% of shares in last quarter. Total pledge stands at 0.88% of promoter holdings

Sun Pharmaceutical Industries Ltd.

10 Apr 2025, 12:00AM

1662.50

-0.41%

Order vacating injunction on Leqselvi a material positive

Buy: Sun Pharmaceutical Industr...

Emkay

The US Court of Appeals has vacated the preliminary injunction against Sun Pharma’s launch of Leqselvi which was granted by the US District Court of New Jersey in Nov-24.

Number of FII/FPI investors increased from 1310 to 1351 in Mar 2025 qtr.

Sun Pharmaceutical Industries Ltd.

11 Mar 2025

1662.50

-0.41%

On a spree to expand specialty portfolio

Buy: Sun Pharmaceutical Industr...

Recommendation Target

ICICI Securities Limited

Sun Pharma (Sun) is acquiring US-based early-stage oncology-focused biotech company Checkpoint Therapeutics (Checkpoint) for an upfront cash payment of USD 4.1/share (total outgo of USD 355mn) and USD 0.7/share in cash in future milestones.

Promoters pledged 0.19% of shares in last quarter. Total pledge stands at 0.88% of promoter holdings

Sun Pharmaceutical Industries Ltd.

10 Mar 2025, 12:00AM

1662.50

-0.41%

Sun Pharma (BUY): Acquiring Checkpoint Therapeutic to widen Specialty portfolio

Buy: Sun Pharmaceutical Industr...

BOB Capital Markets Ltd.

SUNP to acquire Checkpoint Therapeutic for US$ 4.10 a share, at ~66% premium to its last closing price. Deal valued at US$ 355mn

Promoters pledged 0.19% of shares in last quarter. Total pledge stands at 0.88% of promoter holdings

Sun Pharmaceutical Industries Ltd.

01 Feb 2025

1662.50

-0.41%

Sun Pharma (BUY): Strong performance to continue

Buy: Sun Pharmaceutical Industr...

Recommendation Target

BOB Capital Markets Ltd.

Domestic sales grew by 14% in Q3FY25 driven partially by volume/new launches and price hikes. Strong domestic sales growth to continue

Sun Pharmaceutical I.. has an average target of 2105.29 from 7 brokers.

Sun Pharmaceutical Industries Ltd.

21 Jan 2025

1662.50

-0.41%

Addressing the oral IL-23 antagonist challenge to Ilumya

Buy: Sun Pharmaceutical Industr...

Target

Emkay

J&J, in a recent investor interaction, had stated that its oral IL-23 receptor antagonist peptide (Icotrokinra) could potentially compete with existing oral as well as injectable treatment options for moderate to severe plaque psoriasis.